Aflibercept

Grey

Brand Name(s):Zaltrap

Indication:Colorectal cancer – metastatic & previously treated

Rationale:1,2

Considered:Jan-13

Review Date:May-21

Comments:
Drug Safety Update
Minimising the risk of osteonecrosis of the jaw
April 2016
…………………………
NICE TA 307 March 2014 : for full guidance go to http://www.nice.org.uk/nicemedia/live/14474/67002/67002.pdf

1.1 Aflibercept in combination with irinotecan and fluorouracil-based therapy is not
recommended within its marketing authorisation for treating metastatic
colorectal cancer that is resistant to or has progressed after an oxaliplatincontaining
regimen.
1.2 People currently receiving aflibercept in combination with irinotecan and
fluorouracil-based therapy for treating metastatic colorectal cancer that is
resistant to or has progressed after an oxaliplatin-containing regimen should
be able to continue treatment until they and their clinician consider it
appropriate to stop.

…………………………